CDK7

[Prostate] Scientists proposed that alterations in DNA damage response pathway contributed to taxane resistance, and identification of these alterations may provide a potential therapeutic target to resensitize docetaxel-refractory mCRPC to taxane-based therapy.

[European Journal of Pharmacology] Investigators developed a potent inhibitor of cyclin-dependent kinase 7 (CDK7), designated YPN-005, and determined whether it showed any anticancer effects in small cell lung cancer (SCLC), cells, cisplatin or etoposide-resistant cells, or organoids derived from SCLC patients.

[Cell Reports] To identify therapeutic targets in MYC-amplified medulloblastoma, investigators employed a CRISPR-Cas9 essentiality screen targeting 1,140 genes. They identified CDK7 as a mediator of medulloblastoma tumorigenesis.

[Journal of Experimental & Clinical Cancer Research] The anti-tumor activity of hypo-phosphorylated retinoic acid receptor α was investigated in TNBC cell models and a xenograft mouse model.